Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

(2023) Sham Mailankody et al.   NATURE MEDICINE

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

(2023) Paula Rodriguez-Otero et al.   NEW ENGLAND JOURNAL OF MEDICINE

Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation

(2022) Valentín Ortiz-Maldonado et al.   Frontiers in Oncology

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

(2022) Maria-Victoria Mateos et al.   LEUKEMIA

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.

(2022) Saad Zafar Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

(2022) Nico Gagelmann et al.   Lancet Haematology

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

(2022) Raghad Alqazaqi et al.   JAMA Network Open

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

(2021) Philippe Moreau et al.   LANCET ONCOLOGY

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

(2021) Laura Rosiñol et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak

(2021) Alexandra Martínez-Roca et al.   LEUKEMIA RESEARCH

Infectious complications in relapsed refractory multiple myeloma patients after BCMA Car t-cell therapy

(2021) Swetha Kambhampati et al.   Blood Advances

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

(2021) Aina Oliver-Caldés et al.   BLOOD

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

(2021) Yimei Que et al.   Frontiers in Immunology

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

(2021) Valentín Ortiz-Maldonado et al.   Journal for ImmunoTherapy of Cancer

A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe

(2020) Gonzalo Gutiérrez-García et al.   BONE MARROW TRANSPLANTATION

Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma

(2020) Lorena Perez-Amill et al.   HAEMATOLOGICA

Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial

(2020) Maria Castella et al.   Frontiers in Immunology

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

(2020) Valentín Ortíz-Maldonado et al.   MOLECULAR THERAPY

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

(2020) Gils Roex et al.   Journal of Hematology & Oncology

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY